Certara Creates Global Strategic Modeling and Simulation Consultancy

July 8, 2015
Applied Clinical Trials Editorial Staff

Applied Clinical Trials

Certara®, a global biosimulation technology-enabled drug development company, announced the merger of its consulting group, Pharsight Consulting Services.

Certara®, a global biosimulation technology-enabled drug development company, announced the merger of its consulting group, Pharsight Consulting Services (PCS), with Quantitative Solutions, a global pharmacometrics consulting company headquartered in Menlo Park, Calif. The resulting organization is called Certara Strategic Consulting.

This transaction increases Certara’s broadens the company’s modeling capabilities by adding model-based meta-analysis (MBMA) – which uses highly-curated clinical trial data and parametric pharmacology models to increase drug development productivity, quantitatively inform portfolio management, and improve clinical trial success. Another asset is the clinical outcomes databases for analyzing the comparative effectiveness of a new drug within its competitive landscape. Certara has four business units – Certara Strategic Consulting, Certara Software, Simcyp (which focuses on PBPK), and Synchrogenix (which specializes in regulatory writing).

   

Read the full release here.